Skip to content

Advancing breakthroughs in neuroscience to elevate life.

View Our Pipeline

Elevating Lives for More Than 30 Years

For more than three decades, Acadia has been at the forefront of healthcare, elevating lives by providing essential solutions to those who need them most. We pioneered the first and only approved therapies for hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome. Currently, our clinical-stage developments focus on addressing Prader-Willi syndrome, Alzheimer’s disease psychosis, and neuropsychiatric symptoms in CNS disorders.

Innovative therapies for Parkinson’s and Rett syndrome
Advancing a treatment for Alzheimer’s disease
Committed to addressing unmet needs in rare diseases

Fighting Disease So More “You” Shines Through

At Acadia, we are committed to developing therapies in areas with high unmet needs, elevating life to ensure a brighter future for all. United in our commitment, we strive for a healthier tomorrow—embracing diverse perspectives, fostering collaboration, and standing resilient in our mission to elevate life with unwavering dedication.

Latest Perspectives from Acadia

A mother embraces her young daughter in a bedroom, both sharing a tender moment
  • November 13, 2024
  • Acadia Story

November is National Family Caregivers Month, a time to recognize and celebrate the millions of caregivers across the U.S. who provide vital support to their loved ones. These compassionate individuals serve an often-unseen role, offering their time, energy, and unwavering love to care for family members facing chronic illnesses, disabilities, or other health challenges.

Professional headshot of Chirine Fiouzi with dark hair, wearing a blazer against a blue background
  • October 30, 2024
  • Employee Spotlight

News Releases

  • December 19, 2024
  • General
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
  • December 16, 2024
  • General
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • December 11, 2024
  • General
Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
Patient Support

We help patients fight their diseases not only with therapies, but with support, education and connection.

Learn More
Our Medicines

We have FDA-approved treatments for Parkinson’s Disease Psychosis and Rett syndrome.

Discover
Our People

We are a community of unique individuals with the mindset of a scientist, dedication of a healthcare provider and heart of a caregiver.

Join Us

Important Note

You are now being redirected

You are now leaving acadia.com

You are about to leave acadia.com. You will be redirected to a third party website not affiliated with Acadia Pharmaceuticals Inc.
Do you want to continue?

You are leaving our {{LEAVING_REGION}} website and going to our {{ENTERING_REGION}} website, which is in {{ENTERING_LANGUAGE}}.
The information you are about to be referred to may not comply with the local regulatory requirements.
Do you want to continue?

You are now being directed to another Acadia website that contains information about specific treatment(s).
Do you want to continue?

Continue